23:17 , Aug 16, 2019 |  BC Extra  |  Company News

Rinvoq approval bolsters AbbVie's autoimmune portfolio

With Humira adalimumab set to face increasing biosimilar competition internationally this year, AbbVie has notched its second U.S. regulatory win for a successor to its primary revenue driver with FDA’s approval Rinvoq upadacitinib on Friday...
20:31 , Aug 16, 2019 |  BC Extra  |  Company News

Celgene’s myelofibrosis approval sets up key launch for BMS

FDA's approval of potential blockbuster Inrebic fedratinib from Celgene sets up a key launch for BMS in myelofibrosis, an indication for which only one other drug is marketed in the U.S. The agency's decision also...
23:29 , Aug 15, 2019 |  BC Extra  |  Company News

Aug. 15 Company Quick Takes: IQVia's patient portal; plus Gilead/Galapagos and GeneCentric/Select ImmunoGenomics

IQVia launches patient portal  IQVia Holdings Inc. (NYSE:IQV) launched a cloud-based patient portal designed to reduce clinical trial costs associated with patient dropout or lack of follow-up. The platform increases patient engagement with clinical guides,...
00:30 , Jul 27, 2019 |  BioCentury  |  Product Development

How Gilead deal positions Galapagos to become Europe’s next big biotech

Galapagos’ pipeline partnership with Gilead sets the company up to become an independent leader of European biotech for years to come, and provides a template that other platform companies could follow. The July 14 deal...
23:28 , Jul 26, 2019 |  BC Extra  |  Company News

July 26 Company Quick Takes: Lexicon hit by Phase III miss, scuttled deal; plus Xeljanz, Shield, Galapagos, Amarin and more

Sanofi canceling diabetes deal following Phase III misses Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) dropped $2.79 (49%) to $2.90 in after-hours trading Friday after Sanofi (Euronext:SAN; NASDAQ:SNY) said it would terminate the partners’ collaboration on Zynquista sotagliflozin...
22:01 , Jul 19, 2019 |  BioCentury  |  Product Development

Gilead’s $5.1B Galapagos deal threads the needle between M&A and licensing

The structure of Gilead’s partnership with Galapagos gives the U.S. biotech access to all of Galapagos’ programs, without the brain drain that followed its acquisition of Kite. Human capital was the driver behind Gilead Sciences...
15:06 , Jul 15, 2019 |  BC Extra  |  Company News

Galapagos maintains independence, adds R&D firepower with $5.1 billion megadeal with Gilead

A partnership with Gilead allows Galapagos to nearly double the size of its clinical pipeline, with the potential to add new technology platforms via BD, and ensures its independence into the next decade. Under the...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
21:56 , Jun 28, 2019 |  BC Extra  |  Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

AZ's Imfinzi shows survival benefit in Phase III for SCLC  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint...
21:29 , Jun 21, 2019 |  BioCentury  |  Emerging Company Profile

Arcutis: Reformulating dermatology

Arcutis Inc. is using its founders’ topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren’t eligible for biologics. Frazier Healthcare launched the company in 2016...